Because rapamycin reduced the viability of both CD133+ and CD133− pancreatic cancer cells, we expected that decreasing CD133 expression via shRNA would not affect the efficacy of rapamycin treatment. This evidence concerns the gene PROM1 and familial pancreatic carcinoma.